131 related articles for article (PubMed ID: 34382511)
41. Sphingosine analog fingolimod (FTY720) increases radiation sensitivity of human breast cancer cells in vitro.
Marvaso G; Barone A; Amodio N; Raimondi L; Agosti V; Altomare E; Scotti V; Lombardi A; Bianco R; Bianco C; Caraglia M; Tassone P; Tagliaferri P
Cancer Biol Ther; 2014 Jun; 15(6):797-805. PubMed ID: 24657936
[TBL] [Abstract][Full Text] [Related]
42. SLC25A22 Promotes Proliferation and Survival of Colorectal Cancer Cells With KRAS Mutations and Xenograft Tumor Progression in Mice via Intracellular Synthesis of Aspartate.
Wong CC; Qian Y; Li X; Xu J; Kang W; Tong JH; To KF; Jin Y; Li W; Chen H; Go MY; Wu JL; Cheng KW; Ng SS; Sung JJ; Cai Z; Yu J
Gastroenterology; 2016 Nov; 151(5):945-960.e6. PubMed ID: 27451147
[TBL] [Abstract][Full Text] [Related]
43. Spica prunellae promotes cancer cell apoptosis, inhibits cell proliferation and tumor angiogenesis in a mouse model of colorectal cancer via suppression of stat3 pathway.
Lin W; Zheng L; Zhuang Q; Zhao J; Cao Z; Zeng J; Lin S; Xu W; Peng J
BMC Complement Altern Med; 2013 Jun; 13():144. PubMed ID: 23800091
[TBL] [Abstract][Full Text] [Related]
44. The sphingosine kinase 1/sphingosine-1-phosphate pathway mediates COX-2 induction and PGE2 production in response to TNF-alpha.
Pettus BJ; Bielawski J; Porcelli AM; Reames DL; Johnson KR; Morrow J; Chalfant CE; Obeid LM; Hannun YA
FASEB J; 2003 Aug; 17(11):1411-21. PubMed ID: 12890694
[TBL] [Abstract][Full Text] [Related]
45. Novel effects of FTY720 on perinuclear reorganization of keratin network induced by sphingosylphosphorylcholine: Involvement of protein phosphatase 2A and G-protein-coupled receptor-12.
Park MK; Park S; Kim HJ; Kim EJ; Kim SY; Kang GJ; Byun HJ; Kim SH; Lee H; Lee CH
Eur J Pharmacol; 2016 Mar; 775():86-95. PubMed ID: 26872988
[TBL] [Abstract][Full Text] [Related]
46. Assessment of the effect of sphingosine kinase inhibitors on apoptosis,unfolded protein response and autophagy of T-cell acute lymphoblastic leukemia cells; indications for novel therapeutics.
Evangelisti C; Evangelisti C; Teti G; Chiarini F; Falconi M; Melchionda F; Pession A; Bertaina A; Locatelli F; McCubrey JA; Beak DJ; Bittman R; Pyne S; Pyne NJ; Martelli AM
Oncotarget; 2014 Sep; 5(17):7886-901. PubMed ID: 25226616
[TBL] [Abstract][Full Text] [Related]
47. Inhibition of sphingosine kinase 1 enhances cytotoxicity, ceramide levels and ROS formation in liver cancer cells treated with selenite.
Chatzakos V; Rundlöf AK; Ahmed D; de Verdier PJ; Flygare J
Biochem Pharmacol; 2012 Sep; 84(5):712-21. PubMed ID: 22727936
[TBL] [Abstract][Full Text] [Related]
48. PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potential.
Cristóbal I; Manso R; Rincón R; Caramés C; Senin C; Borrero A; Martínez-Useros J; Rodriguez M; Zazo S; Aguilera O; Madoz-Gúrpide J; Rojo F; García-Foncillas J
Mol Cancer Ther; 2014 Apr; 13(4):938-47. PubMed ID: 24448818
[TBL] [Abstract][Full Text] [Related]
49. Therapeutic potential of targeting sphingosine kinase 1 in prostate cancer.
Pchejetski D; Böhler T; Stebbing J; Waxman J
Nat Rev Urol; 2011 Sep; 8(10):569-678. PubMed ID: 21912422
[TBL] [Abstract][Full Text] [Related]
50. Sphingosine kinase isoforms regulate oxaliplatin sensitivity of human colon cancer cells through ceramide accumulation and Akt activation.
Nemoto S; Nakamura M; Osawa Y; Kono S; Itoh Y; Okano Y; Murate T; Hara A; Ueda H; Nozawa Y; Banno Y
J Biol Chem; 2009 Apr; 284(16):10422-32. PubMed ID: 19240026
[TBL] [Abstract][Full Text] [Related]
51. The regulation of p53, p38 MAPK, JNK and XBP-1s by sphingosine kinases in human embryonic kidney cells.
Alsanafi M; Kelly SL; McNaughton M; Merrill AH; Pyne NJ; Pyne S
Biochim Biophys Acta Mol Cell Biol Lipids; 2020 Apr; 1865(4):158631. PubMed ID: 31954175
[TBL] [Abstract][Full Text] [Related]
52. Tumor necrosis factor induces the loss of sphingosine kinase-1 by a cathepsin B-dependent mechanism.
Taha TA; Kitatani K; Bielawski J; Cho W; Hannun YA; Obeid LM
J Biol Chem; 2005 Apr; 280(17):17196-202. PubMed ID: 15710602
[TBL] [Abstract][Full Text] [Related]
53. Therapeutic potential of targeting SK1 in human cancers.
Alshaker H; Sauer L; Monteil D; Ottaviani S; Srivats S; Böhler T; Pchejetski D
Adv Cancer Res; 2013; 117():143-200. PubMed ID: 23290780
[TBL] [Abstract][Full Text] [Related]
54. Hwang-Heuk-San induces apoptosis in HCT116 human colorectal cancer cells through the ROS-mediated activation of caspases and the inactivation of the PI3K/Akt signaling pathway.
Lee MH; Hong SH; Park C; Kim GY; Leem SH; Choi SH; Keum YS; Hyun JW; Kwon TK; Hong SH; Choi YH
Oncol Rep; 2016 Jul; 36(1):205-14. PubMed ID: 27221553
[TBL] [Abstract][Full Text] [Related]
55. FTY720 induces apoptosis of chronic myelogenous leukemia cells via dual activation of BIM and BID and overcomes various types of resistance to tyrosine kinase inhibitors.
Kiyota M; Kuroda J; Yamamoto-Sugitani M; Shimura Y; Nakayama R; Nagoshi H; Mizutani S; Chinen Y; Sasaki N; Sakamoto N; Kobayashi T; Matsumoto Y; Horiike S; Taniwaki M
Apoptosis; 2013 Nov; 18(11):1437-1446. PubMed ID: 23851982
[TBL] [Abstract][Full Text] [Related]
56. Ceramide conversion to sphingosine-1-phosphate is essential for survival in C3H10T1/2 cells.
Castillo SS; Teegarden D
J Nutr; 2001 Nov; 131(11):2826-30. PubMed ID: 11694603
[TBL] [Abstract][Full Text] [Related]
57. Sphingoid bases and ceramide induce apoptosis in HT-29 and HCT-116 human colon cancer cells.
Ahn EH; Schroeder JJ
Exp Biol Med (Maywood); 2002 May; 227(5):345-53. PubMed ID: 11976405
[TBL] [Abstract][Full Text] [Related]
58. HSP-70 mitigates LPS/SKI-induced cell damage by increasing sphingosine kinase 1 (SK1).
Ding XZ; Feng XR; Borschel RH; Nikolich MP; Feng J; Li YS; Hoover DL
Prostaglandins Other Lipid Mediat; 2010 Jun; 92(1-4):1-7. PubMed ID: 20123033
[TBL] [Abstract][Full Text] [Related]
59. Isobavachalcone isolated from
Li Y; Qin X; Li P; Zhang H; Lin T; Miao Z; Ma S
Drug Des Devel Ther; 2019; 13():1449-1460. PubMed ID: 31118579
[No Abstract] [Full Text] [Related]
60. Potential of a sphingosine 1-phosphate receptor antagonist and sphingosine kinase inhibitors as targets for multiple myeloma treatment.
Tanaka Y; Okabe S; Ohyashiki K; Gotoh A
Oncol Lett; 2022 Apr; 23(4):111. PubMed ID: 35251342
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
